Advanced Digestive Neuroendocrine Neoplasms Split Into Two Very Different Prognostic Groups
The NORDIC NEC 2 study places digestive high-grade neuroendocrine neoplasms back under an uncomfortable clinical spotlight. In a prospective multicenter cohort of 639 patients, advanced disease behaved very differently depending on whether the tumor was classified as neuroendocrine carcinoma (NEC) or neuroendocrine tumor G3 (NET G3), and those differences were large enough to reshape day-to-day treatment expectations.
Among the 427 patients with NEC and 117 with NET G3 who received palliative chemotherapy, early treatment failure was common, especially in NEC. Immediate progression occurred in 41% of NEC and 24% of NET G3. Median progression-free survival reached only 3.4 months for NEC, compared with 7.4 months for NET G3. Median overall survival was 7.4 months in NEC and 21.8 months in NET G3.
Those numbers are not subtle. They describe a disease group in which a standard first-line approach can fail before it has time to matter.
Central Pathology Review Sharpened the Difference Between NEC and NET G3
The study used centralized pathological re-evaluation before comparing treatment outcomes, a critical step in a field where morphology, proliferation rate, and clinical behavior do not always align neatly. Digestive high-grade neuroendocrine neoplasms were once grouped together more broadly, but modern classification separates poorly differentiated NEC from well-differentiated NET G3 because they do not share the same biology or prognosis.
That distinction has direct therapeutic consequences. NEC has often been treated with platinum plus etoposide by extrapolation from small-cell lung cancer, yet the benefit has remained limited. NET G3, by contrast, tends to follow a less explosive clinical course and has frequently been managed with temozolomide-based therapy or FOLFOX, especially when the disease does not appear overtly aggressive. The NORDIC NEC 2 dataset gives that clinical instinct stronger empirical grounding.
Platinum-Based Therapy Left NET G3 at a Disadvantage
The most consequential finding for NET G3 was not just its longer survival, but the study’s conclusion that an initial sub-effective platinum-based treatment could not be rescued later. Platinum-based treatment emerged as a significant factor for both overall survival and progression-free survival in NET G3, signaling that early regimen choice mattered in a disease already known to be biologically distinct from NEC.
In practical terms, the opening cycle matters because a poorly matched regimen may consume time that NET G3 patients do not have in abundance. Once disease control is lost early, later-line therapy may not recover the gap. For a malignancy that is still uncommon and frequently managed by extrapolated principles, that is a hard result to ignore.
Ki-67, Performance Status, and Liver Chemistry Carried Real Prognostic Weight
For NEC, overall survival was associated with performance status, Ki-67 above 55%, alkaline phosphatase, age, and sex. Progression-free survival was associated with colorectal primary and performance status. These variables read like the bedside fingerprint of an illness that is being driven by both tumor biology and host reserve.
Ki-67 above 55% has long been treated as a marker of more aggressive proliferation, and the study reinforces that threshold as clinically meaningful within NEC. Performance status also remained a central predictor, which is unsurprising in a cohort that likely included frail patients with limited physiologic reserve. Alkaline phosphatase added another layer, likely reflecting hepatic involvement or biliary injury in a population where metastatic burden often falls heavily on the liver.
A brief point deserves emphasis: the biology and the patient’s general condition moved survival in the same direction.
NEC With Ki-67 Below 55% Did Not Gain a Clear Survival Advantage From Treatment Choice
One of the more nuanced observations concerns NEC with Ki-67 below 55%. In this subgroup, overall survival was similar across treatment approaches. That finding aligns with the long-standing uncertainty around how best to treat lower-proliferation NEC, where the tumor can look histologically like carcinoma while behaving less uniformly than classic small-cell analogues.
The absence of a clear survival separation here suggests that not every NEC with a lower Ki-67 index should be expected to respond identically to platinum-etoposide. It also supports the idea that NEC is not a single therapeutic entity; proliferation rate, morphology, and patient fitness all appear to modulate outcome. For clinicians, this is the kind of subgroup that often demands closer consideration of alternatives rather than reflexive protocol use.
Elderly Patients and Poor Performance Status Pulled Survival Downward
The overall survival in this cohort was shorter than expected, and the investigators attributed part of that to the inclusion of elderly patients and patients with poor performance status. That matters because it suggests the cohort may be more representative of real-world practice than of a selected trial population. Real-world cohorts often expose the distance between guideline assumptions and the clinical realities of advanced cancer care.
In a disease as uncommon as digestive high-grade neuroendocrine neoplasia, prospective enrollment across centers can capture patients who would never make it into tightly controlled studies. That improves external validity, but it also drags outcome estimates downward when frailer patients are included. The result is sobering, yet clinically honest.
A Rare Cohort, Better Defined, Still in Need of Better First-Line Strategies
NORDIC NEC 2 strengthens the argument that NEC and NET G3 should not be treated as interchangeable labels. Their outcomes diverged sharply, their prognostic variables were not identical, and first-line regimen choice clearly mattered, especially in NET G3. The study also helps explain why older survival estimates for mixed high-grade cohorts have often looked imprecise: lumping together two biologically distinct diseases obscures the true signal.
For NEC, the persistent problem remains early progression and short survival despite platinum-based treatment. For NET G3, the central issue is matching the initial regimen to the tumor’s behavior before valuable time is lost. The dataset also leaves open the practical question of how to refine treatment selection beyond morphology and Ki-67, particularly in patients with borderline proliferation rates or limited performance status.
The cohort does not solve those problems. It does, however, make the current limits of palliative chemotherapy in advanced digestive high-grade neuroendocrine neoplasms harder to ignore.